Division of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, 13121 East 17th Avenue, MS 8402, Aurora, CO, 80045, USA.
Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
J Nephrol. 2023 Jul;36(6):1591-1597. doi: 10.1007/s40620-023-01634-8. Epub 2023 Apr 25.
Preterm newborns are at risk for patent ductus arteriosus, and non-steroidal anti-inflammatory drugs are often used to facilitate patent ductus arteriosus closure. Acute kidney injury is common in critically ill neonates and may be caused by non-steroidal anti-inflammatory drugs. We sought to describe the incidence of acute kidney injury among preterm infants receiving indomethacin and determine whether acute kidney injury during indomethacin therapy is associated with subsequent patent ductus arteriosus closure.
Retrospective cohort including neonates < 33 weeks gestational age, admitted to two level IIIb neonatal intensive care units between November 2016 and November 2019, who received indomethacin in the first 2 weeks of life. Acute kidney injury in the 7-day period after treatment was defined by neonatal modified Kidney Disease Improving Global Outcomes (KDIGO) criteria. Patent ductus arteriosus closure was defined clinically and/or via echocardiogram. Clinical characteristics were extracted from medical records. Association between acute kidney injury during treatment and successful closure of patent ductus arteriosus was evaluated using chi-square tests and logistic regression.
One hundred fifty preterm infants were included; acute kidney injury occurred in 8% (all KDIGO Stage 1). Patent ductus arteriosus closed in 52.9% of the non-acute kidney injury group and 66.7% of the acute kidney injury group (p = 0.55). Serum creatinine was checked a mean of 3.1 times in the acute kidney injury group and 2.2 times in the non-acute kidney injury group. There was no difference in survival.
We found no association between acute kidney injury during indomethacin therapy and patent ductus arteriosus closure. Paucity of serum creatinine values likely underdiagnosed acute kidney injury. Surveillance of kidney function during indomethacin therapy using more sensitive renal biomarkers may better identify infants who develop acute kidney injury in the context of non-steroidal anti-inflammatory drug use.
早产儿存在动脉导管未闭的风险,通常使用非甾体抗炎药来促进动脉导管未闭的闭合。危重新生儿中急性肾损伤很常见,可能由非甾体抗炎药引起。我们旨在描述接受吲哚美辛治疗的早产儿中急性肾损伤的发生率,并确定吲哚美辛治疗期间急性肾损伤是否与随后的动脉导管未闭闭合相关。
这是一项回顾性队列研究,纳入了 2016 年 11 月至 2019 年 11 月期间在 2 家 3 级 B 新生儿重症监护病房住院、胎龄<33 周的新生儿,他们在生命的前 2 周内接受了吲哚美辛治疗。治疗后 7 天内发生的急性肾损伤根据新生儿改良肾脏病改善全球结局(KDIGO)标准定义。动脉导管未闭的闭合通过临床和/或超声心动图定义。从病历中提取临床特征。采用卡方检验和逻辑回归评估治疗期间急性肾损伤与动脉导管未闭成功闭合之间的关系。
共纳入 150 例早产儿;急性肾损伤发生率为 8%(均为 KDIGO 1 期)。非急性肾损伤组中动脉导管未闭闭合的比例为 52.9%,急性肾损伤组为 66.7%(p=0.55)。急性肾损伤组的血清肌酐检查平均为 3.1 次,非急性肾损伤组为 2.2 次。两组间的存活率无差异。
我们发现吲哚美辛治疗期间的急性肾损伤与动脉导管未闭闭合之间无关联。血清肌酐值的缺乏可能导致急性肾损伤漏诊。在使用非甾体抗炎药时,使用更敏感的肾生物标志物监测吲哚美辛治疗期间的肾功能可能更好地识别发生急性肾损伤的婴儿。